Posted by Michael Wonder on 21 May 2024
Ractigen Therapeutics secures FDA fast track designation for RAG-01, a first in class saRNA therapy
21 May 2024 - Ractigen Therapeutics proudly announces that its flagship program, RAG-01, has been granted fast track designation by the US FDA.
RAG-01 is currently undergoing a Phase I clinical trial in Australia for the treatment of non-muscle invasive bladder cancer. The trial, initiated in December 2023, has successfully enrolled and dosed three patients, demonstrating the program's progress in clinical development.
